炎症性微环境-响应性微球载体调节肠道微生物群和肠道炎症,用于炎症性肠道疾病中的肠道干细胞利基重塑
Xing Zhao1,2, Liya Wang1, Ya-Jun Fu3
1Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu 610041, China.
ACS nano
|March 24, 2025
概括
这项研究开发了微球载体,通过重塑肠干细胞 (ISC) 利基来治疗炎症性肠病 (IBD). 这些微球提供MXene和l-arginine以减少炎症并促进肠道愈合.
科学领域:
- 胃肠病学 胃肠病学
- 生物材料科学 生物材料科学
- 免疫学 免疫学 免疫学
背景情况:
- 肠干细胞 (ISC) 维持肠表皮,但在炎症性肠病 (IBD) 中受损.
- 在IBD期间,ISC利基信号被破坏,阻碍了上皮细胞的修复.
- 目前的IBD治疗努力恢复ISC位和肠道屏障功能.
研究的目的:
- 开发响应的微球车辆,用于向IBD治疗.
- 为了重塑ISC位并恢复肠上皮质屏障功能.
- 调查MXene和l-阿尔金因在IBD治疗中的治疗潜力.
主要方法:
- 使用乳液技术制造肠道炎症微环境响应的微球.
- 针对性地将MXene和l-arginine输送到结肠炎症部位.
- 评估微球对肠道微生物群,免疫反应和ISC利基的影响.
主要成果:
- 微球有效地准了结肠炎症.
- 同时提供MXene和l-arginine调节肠道菌群和免疫反应.
- 将l-氨酸转化为氧化调节了微生物群;MXene稳定了免疫常态稳定.
- 微球显示出显著的抗炎性质,促进了上皮的修复和ISC的重塑.
结论:
- 响应微球通过准ISC位,为IBD治疗提供了一个有希望的策略.
- 开发的输送系统有效调节肠道环境和免疫反应.
- 抗氧化微球间接支持ISC功能和肠道再生,突出其治疗潜力.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
288
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
288
Irritable Bowel Syndrome I: Introduction
211
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
211
Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106


